1. Home
  2. CELU vs IXHL Comparison

CELU vs IXHL Comparison

Compare CELU & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELU
  • IXHL
  • Stock Information
  • Founded
  • CELU 2016
  • IXHL 2001
  • Country
  • CELU United States
  • IXHL Australia
  • Employees
  • CELU N/A
  • IXHL N/A
  • Industry
  • CELU Biotechnology: Pharmaceutical Preparations
  • IXHL
  • Sector
  • CELU Health Care
  • IXHL
  • Exchange
  • CELU Nasdaq
  • IXHL Nasdaq
  • Market Cap
  • CELU 42.2M
  • IXHL 35.6M
  • IPO Year
  • CELU N/A
  • IXHL N/A
  • Fundamental
  • Price
  • CELU $3.86
  • IXHL $0.66
  • Analyst Decision
  • CELU Buy
  • IXHL
  • Analyst Count
  • CELU 1
  • IXHL 0
  • Target Price
  • CELU $6.00
  • IXHL N/A
  • AVG Volume (30 Days)
  • CELU 66.2K
  • IXHL 141.6M
  • Earning Date
  • CELU 10-15-2025
  • IXHL 09-29-2025
  • Dividend Yield
  • CELU N/A
  • IXHL N/A
  • EPS Growth
  • CELU N/A
  • IXHL N/A
  • EPS
  • CELU N/A
  • IXHL N/A
  • Revenue
  • CELU $44,590,000.00
  • IXHL $98,000.00
  • Revenue This Year
  • CELU $23.29
  • IXHL $2,538.49
  • Revenue Next Year
  • CELU N/A
  • IXHL $249.95
  • P/E Ratio
  • CELU N/A
  • IXHL N/A
  • Revenue Growth
  • CELU 138.11
  • IXHL N/A
  • 52 Week Low
  • CELU $1.00
  • IXHL $0.08
  • 52 Week High
  • CELU $5.22
  • IXHL $3.12
  • Technical
  • Relative Strength Index (RSI)
  • CELU 60.90
  • IXHL 55.91
  • Support Level
  • CELU $3.52
  • IXHL $0.60
  • Resistance Level
  • CELU $4.01
  • IXHL $0.92
  • Average True Range (ATR)
  • CELU 0.34
  • IXHL 0.08
  • MACD
  • CELU -0.01
  • IXHL 0.02
  • Stochastic Oscillator
  • CELU 64.84
  • IXHL 52.17

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: